MUSCLE INVASIVE BLADDER CARCINOMA
Clinical trials for MUSCLE INVASIVE BLADDER CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUSCLE INVASIVE BLADDER CARCINOMA trials appear
Sign up with your email to follow new studies for MUSCLE INVASIVE BLADDER CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough bladder cancer cases
Disease control CompletedThis early-stage study tested a combination of two drugs—CG0070 (a virus that targets cancer cells) and nivolumab (an immunotherapy that boosts the immune system)—in 21 people with muscle-invasive bladder cancer who were not eligible for standard chemotherapy. The goal was to see…
Matched conditions: MUSCLE INVASIVE BLADDER CARCINOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immunotherapy plus chemo shows promise for rare bladder cancers
Disease control CompletedThis pilot study tested whether giving pembrolizumab (an immunotherapy) along with standard chemotherapy before surgery could help people with rare types of muscle-invasive bladder cancer. 17 participants received the combination, and researchers measured how many had no cancer l…
Matched conditions: MUSCLE INVASIVE BLADDER CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 26, 2026 17:36 UTC
-
Tiny DNA fragments in blood may predict bladder cancer treatment success
Knowledge-focused CompletedThis study looked at whether measuring bits of tumor DNA in blood and urine (called ctDNA) is possible in people with muscle-invasive bladder cancer receiving a combination of surgery, radiation, and chemotherapy. The goal was to see if this approach could help monitor how well t…
Matched conditions: MUSCLE INVASIVE BLADDER CARCINOMA
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC